India flags Abhayrab rabies-vaccine batch as substandard, probes possible counterfeit
India’s drug regulator flagged Abhayrab batch KE25012 after a potency-test failure and directed heightened distribution vigilance while investigating whether the product is spurious. Manufacturer Indian Immunologicals had previously reported a separate suspected counterfeit batch.
What happened
India’s drug regulator flagged Abhayrab batch KE25012 as substandard after a potency-test failure and is probing possible counterfeiting. Officials ordered
Key facts
- Batch KE25012
- More than 210 million doses supplied
- 40% domestic rabies-vaccine market share
- Batch KA24014
- Estimated 5,726 annual human rabies deaths
- Exports to more than 40 countries
Why this matters
The incident highlights strategic value in traceability, anti-counterfeit packaging, and quality-control capabilities, while making Abhayrab-related partnerships or assets materially higher diligence risks.
What to watch
- Regulator confirmation that KE25012 is counterfeit, manufacturing-defective, or limited to potency degradation in distribution.
- Any expansion of the alert, recall, testing order, or enforcement action to other Abhayrab lots, facilities, or states.
- Reported adverse events, treatment failures, or hospital advisories connected to the flagged batch.
- Indian Immunologicals' disclosure of root cause, replacement volumes, supply impact, and corrective-action timeline.
- Competitor supply actions, government tender changes, or procurement switches by major hospitals and public-health programs.
- Evidence that counterfeit products entered authorized distribution channels rather than informal markets.
- Quarantine and trace KE25012 inventory across distributors, hospitals, clinics, and pharmacies; provide a clear verification and return process.
- Publish lot-level testing, investigation milestones, and guidance for providers treating patients who may have received the affected product.
- Coordinate with regulators and law enforcement on anti-counterfeit packaging checks, distributor chain-of-custody records, and suspect-stock reporting.
- Increase authentication measures such as serialized verification, tamper-evident packaging, and provider/pharmacy education.
- Secure contingency supply and communicate allocation plans to avoid treatment interruptions or procurement defections.